IMVIQ Stock - IMV Inc.
Unlock GoAI Insights for IMVIQ
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | $2,352.646 | $45,166 | $60,204 |
| Gross Profit | N/A | N/A | $2,352.646 | $45,166 | $60,204 |
| Gross Margin | N/A | N/A | 100.0% | 100.0% | 100.0% |
| Operating Income | $-39,494,000 | $-35,682,000 | $-27,539,288.354 | $-20,390,119 | $-15,382,187 |
| Net Income | $-37,991,000 | $-36,589,000 | $-27,333,824.775 | $-20,948,961.547 | $-16,104,637.93 |
| Net Margin | N/A | N/A | -1161833.3% | -46382.1% | -26750.1% |
| EPS | $-4.55 | $-4.93 | $-4.10 | $-4.22 | $-3.68 |
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Visit WebsiteEarnings History & Surprises
IMVIQEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2024 | May 10, 2024 | $-1.17 | — | — | — |
Q1 2024 | Mar 14, 2024 | $-1.31 | — | — | — |
Q4 2023 | Oct 20, 2023 | $-1.20 | — | — | — |
Q3 2023 | Aug 18, 2023 | $-1.03 | — | — | — |
Q2 2023 | Jun 29, 2023 | $-1.03 | — | — | — |
Q1 2023 | Mar 16, 2023 | $-1.20 | $-0.99 | +17.5% | ✓ BEAT |
Q3 2022 | Sep 30, 2022 | $-1.35 | $-0.79 | +41.4% | ✓ BEAT |
Q2 2022 | Jun 30, 2022 | $-1.29 | $-0.93 | +27.3% | ✓ BEAT |
Q1 2022 | Mar 31, 2022 | $-1.38 | $-1.02 | +25.9% | ✓ BEAT |
Q4 2021 | Dec 31, 2021 | — | $-1.12 | — | — |
Q3 2021 | Sep 30, 2021 | $-1.38 | $-1.04 | +24.8% | ✓ BEAT |
Q2 2021 | Jun 30, 2021 | — | $-0.89 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.82 | — | — |
Q3 2020 | Sep 30, 2020 | — | $-0.71 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.68 | — | — |
Q1 2020 | Mar 31, 2020 | — | $-0.95 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-0.79 | — | — |
Q3 2019 | Sep 30, 2019 | — | $-0.89 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-0.58 | — | — |
Q1 2019 | Mar 31, 2019 | — | $-0.71 | — | — |
Latest News
Frequently Asked Questions about IMVIQ
What is IMVIQ's current stock price?
What is the analyst price target for IMVIQ?
What sector is IMV Inc. in?
What is IMVIQ's market cap?
Does IMVIQ pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to IMVIQ for comparison